Tag: pegzilarginase

December 12, 2018

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency

Aeglea BioTherapeutics (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic...
September 4, 2018

Aeglea BioTherapeutics Announces Positive Clinical Update

Aeglea BioTherapeutics issued an update on Tuesday for its ongoing Phase 1/2 trial of pegzilarginase in patients with a rare...
September 4, 2018

Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase

Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare...